BASP1 is a membrane‐bound protein that plays a promotional or inhibitory role in a variety of tumors; however, its role in gastric cancer (GC) and in the immune microenvironment has not been reported. The objectives of this study were to determine whether BASP1 is a valuable prognostic marker for GC and to explore its role in the immune microenvironment of GC. The expression level of BASP1 in GC was analyzed based on the TCGA dataset and further verified using GSE54129 and GSE161533 datasets, immunohistochemistry, and western blotting. The association between BASP1 and clinicopathological characteristics, as well as its predictive value, were examined using the STAD dataset. Cox regression analysis was performed to determine whether BASP1 can be used as an independent prognostic indicator for GC, and a nomogram was constructed to predict OS. The association between BASP1 and immune cell infiltration, immune checkpoints, and immune cell markers was confirmed by enrichment analysis, as well as analysis based on the TIMER and GEPIA databases. BASP1 was observed to be highly expressed in GC and was associated with a poor prognosis. The expression of BASP1 was positively correlated with the expression of immune checkpoints and immune cell markers, as well as immune cell infiltration. Thus, BASP1 may serve as a standalone prognostic indicator for GC. BASP1 is highly correlated with immune processes, and its expression is positively correlated with the degree of immune cell infiltration, immune checkpoints, and immune cell markers.

Background. The lncRNA taurine upregulated gene 1 (TUG1) is a recently identified potential biomarker in cancer. However, its prognostic role in various cancers is inconsistent among published data. We conducted this meta-analysis to comprehensively confirm the prognostic effect of TUG1 in malignant tumors. Methods. We systemically analyzed the prognostic-predictive capacity of TUG1 through amplifying sample sizes and cancer types. STATA 12.0 was applied for this meta-analysis. Results. A total of 57 eligible studies were included in our meta-analysis. The pooled results suggested that overexpression of TUG1 was significantly correlated with unfavorable overall survival (OS) ( , ), shorter recurrence-free survival (RFS) ( , ), and shorter event-free survival (EFS) ( , ) in patients with cancer. In the subgroup analysis by cancer type, elevated TUG1 expression was associated with poorer survival in patients with gastrointestinal cancer, urinary tumors, gynecological tumors, hematological tumors, and osteosarcoma. However, high expression of TUG1 in respiratory tumors indicated a better prognosis. There was no correlation between high TUG1 expression and OS in patients with head and neck neoplasms or melanoma. Additionally, overexpression of TUG1 was found to be correlated with low-grade tumor differentiation, advanced tumor stage, positive lymphatic metastasis, and positive distant metastasis. Conclusions. High TUG1 expression correlates with poor prognosis and advanced clinicopathological features, verifying the prognostic-predictive capacity of TUG1 in tumors, especially in gastrointestinal cancer, urinary tumors, gynecological tumors, hematological tumors, and osteosarcoma. Meanwhile, the prognostic role of TUG1 in respiratory tumor may be opposite to other tumors.

In this study, a novel pyrazole amide derivative designated T1, was designed and synthesized to explore its therapeutic potential for liver cancer. The compound was evaluated for its effects on liver cancer cell viability, proliferation, migration, invasion, and apoptosis both in vitro and in vivo. The in vitro evaluation was conducted using several experimental techniques, including the CCK-8 assay, colony formation assay, transwell migration assay, immunofluorescence, and western blotting. T1 demonstrated an IC50 of 47.7 μg/mL in HuH7 liver cancer cells, showing significantly improved efficacy compared to standard chemotherapeutics, including capecitabine and 5-fluorouracil, and comparable efficacy to sorafenib (IC50 of 55.6 μg/ml). Furthermore, T1 significantly inhibited the proliferation, migration, and invasion of HepG2 and HuH-7 cells, while also inducing apoptosis. Transcriptome sequencing and western blotting analyses revealed that T1 modulates the MAPK signaling pathway, leading to the altered expression of apoptosis-related proteins, which contributes to the observed anti-cancer effects. In vivo studies using a HuH-7 xenograft mouse model confirmed the efficacy of T1, with tumor growth inhibition similar to that of sorafenib. These findings suggest that T1 holds significant promise as a potential chemotherapeutic agent for the treatment of hepatocellular carcinoma (HCC).

Background: Severe obesity is associated with both circadian rhythm disturbances and cognitive deficits; however, the specific role of melatonin rhythmicity in neurocognitive dysfunction remains poorly understood. This study aimed to investigate the relationship between detailed salivary melatonin secretion profiles and cognitive performance across multiple domains in patients with severe obesity awaiting bariatric surgery. Methods: A total of 54 participants underwent salivary melatonin sampling at seven overnight time points. Cosinor analysis was used to extract circadian parameters, including mesor, amplitude, and acrophase. Neuropsychological assessments evaluated executive function, processing speed, memory, and general intelligence. The primary outcome was performance on the Stroop test, which captures core aspects of processing speed, executive function, and attention. Other neuropsychological measures, including IQ, MQ, and Trail Making Test performance, were considered secondary outcomes. Multivariable linear regression models, adjusted for demographic and metabolic covariates, were used to examine the associations between melatonin parameters and cognitive outcomes. Results: Participants exhibited substantial interindividual variation in melatonin profiles. A later melatonin acrophase was significantly associated with reduced processing speed, executive function, and attention, as reflected by longer completion times on the Stroop test ( β values ranged from 3.11 to 9.90, FDR-adjusted P < 0.05). The amplitude of melatonin secretion demonstrated a much weaker association with cognitive performance. Although nominal associations were observed between lower amplitude and slower Stroop Color Naming ( β = −1.22, 95% CI: −2.26 to −0.18, P = 0.023) and Incongruent ( β = −2.43, 95% CI: −4.74 to −0.11, P = 0.040) times, neither of these findings remained significant after FDR correction, indicating they may be due to chance. Conclusions: A later melatonin acrophase was associated with poorer cognitive performance in individuals with severe obesity undergoing evaluation for bariatric surgery. Larger longitudinal studies are needed to validate this association and determine whether changes in circadian timing are related to cognitive trajectories after bariatric surgery.